Microarray analysis reveals potential target genes of NF-κB2/p52 in LNCaP prostate cancer cells

Prostate

Volumn 70, Issue 3, 2010, Pages 276-287

  Nadiminty, Nagalakshmi ^a   Dutt, Smitha ^a   Tepper, Clifford ^a   Gao, Allen C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

LNCaP; Microarray; NF B2 p52; Prostate

Indexed keywords

COMPLEMENTARY DNA; CXCL1 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 2; PROTEIN P52; RNA;

ADENOVIRUS; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL INTERACTION; CELL MOTION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MICROCHIP ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MICROARRAY ANALYSIS; NF-KAPPA B P52 SUBUNIT; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; UP-REGULATION;

EID: 75649120392     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21062     Document Type: Article

References (43)

1. Karin M. Nuclear factor-[kappa]B in cancer development and progression. Nature 2006;441(7092):431-436.
2. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25(51):6817-6830.
3. Baud V, Karin M. Is NF-[kappa]B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8(1):33-40.
4. Pomerantz JL, Baltimore D. Two pathways to NF-[kappa]B. Mol Cell 2002;10(4):693-695.
5. Xiao G, Harhaj EW, Sun S-C. NF-[kappa]B-inducing kinase regulates the processing of NF-[kappa]B2 p100. Mol Cell 2001;7(2):401-409.
6. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. The lymphotoxin-[beta] receptor induces different patterns of gene expression via two NF-[kappa]B pathways. Immunity 2002;17(4):525-535.
7. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-[kappa]B2 in maturing B cells. Nat Immunol 2002;3(10):958-965.
8. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, Klaus GG, Johnston LH, Ley SC. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21(20):5375-5385.
9. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-κB p100 processing involves CBP/ p300-mediated acetylation. Proc Natl Acad Sci USA 2006;103(19):7264-7269.
10. Edwards J, Krishna NS, Grigor KM, Bartlett JMS. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-556.
11. Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21(14):2673-2678.
12. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-6415.
13. D'Antonio JM, Ma C, Monzon FA, Pflug BR. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 2008;68(7):698-714.
14. Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. BioEssays 2007;29(12):1227-1238.
15. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16(1):37-44.
16. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7(6):591-604.
17. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urologic Oncol 2009;27(1):36-41.
18. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 1996;271(39):24151-24156.
19. Chen CD, Sawyers CL. NF-{kappa}B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22(8):2862-2870.
20. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 2005;93(9):1019-1023.
21. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107(3):241-246.
22. Ross JS, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman RP Jr, Kaur P, Gray K, Stringer B. Expression of nuclear factor-{kappa}B and I{kappa}B{alpha} proteins in prostatic adenocarcinomas: Correlation of nuclear factor-{kappa}B immunoreactivity with disease recurrence. Clin Cancer Res 2004;10(7):2466-2472.
23. Dejardin E. The alternative NF-[kappa]B pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem Pharmacol 2006;72(9):1161-1179.
24. Jost PJ, Ruland J. Aberrant NF-{kappa}B signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood 2007;109(7):2700-2707.
25. Nadiminty N,Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008;68(16):1725-1733.
26. Connelly L, Robinson-Benion C, Chont M, Saint-Jean L, Li H, Polosukhin VV, Blackwell TS, Yull FE. A transgenic model reveals important roles for the NF-{kappa}B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 2007;282(13):10028-10035.
27. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008;8(1):41.
28. Davis RE, Staudt LM. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol 2002;9(4):333-338.
29. Keutgens A, Robert I, Viatour P, Chariot A. Deregulated NF-[kappa]B activity in haematological malignancies. Biochem Pharmacol 2006;72(9):1069-1080.
30. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-648.
31. Schweizer L, Rizzo C, Spires T, Platero JS, Wu Q, Lin T-A, Gottardis M, Attar R. The androgen receptor can signal through Wnt/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 2008;9(1):4.
32. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W, Zhang Y. Identification and, validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145(8):3913- 3924.
33. DePrimo S, Diehn M, Nelson J, Reiter R, Matese J, Fero M, Tibshirani R, Brown P, Brooks J. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 2002;3(7):research0032.0031- research0032.0012.
34. Corcoran NM, Costello AJ, Hovens CM. Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int 2006;97(6):1149-1153.
35. McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008;22(2):373-388.
36. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-448.
37. Helenius MA, Savinainen KJ, Bova GS, Visakorpi T. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. BJU Int 2006;97(2):404-409.
38. Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, Ornstein DK, Tyson DR. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. Int J Cancer 2009;124(1):68-74.
39. Bektic J, Pfeil K, Berger AP, Ramoner R, Pelzer A, Schäfer G, Kofler K, Bartsch G, Klocker H. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005;64(4):332-340.
40. Yuen H-F, Chua C-W, Chan Y-P, Wong Y-C, Wang XK-WC. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 2007;50(5):648-658.
41. Brakenhielm E, Burton JB, Johnson M, Chavarria N, Morizono K, Chen I, Alitalo KLW. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer 2007;121(10):2153-2161.
42. Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008;43(2):194-199.
43. Sarkar FH, Li Y. NF-kappaB: A potential target for cancer chemoprevention and therapy. Front Biosci 2008;13:2950-2959.